PTHrP Regulates Fatty Acid Metabolism via Novel lncRNA in Breast Cancer Initiation and Progression Models.
Rui ZhangJiarong LiDunarel BadescuAndrew C KaraplisJiannis RagoussisRichard KremerPublished in: Cancers (2023)
Parathyroid hormone-related peptide (PTHrP) is the primary cause of malignancy-associated hypercalcemia (MAH). We previously showed that PTHrP ablation, in the MMTV-PyMT murine model of breast cancer (BC) progression, can dramatically prolong tumor latency, slow tumor growth, and prevent metastatic spread. However, the signaling mechanisms using lineage tracing have not yet been carefully analyzed. Here, we generated Pthrpflox/flox; Cre+ mT/mG mice (KO) and Pthrpwt/wt; Cre+ mT/mG tumor mice (WT) to examine the signaling pathways under the control of PTHrP from the early to late stages of tumorigenesis. GFP+ mammary epithelial cells were further enriched for subsequent RNA sequencing (RNAseq) analyses. We observed significant upregulation of cell cycle signaling and fatty acid metabolism in PTHrP WT tumors, which are linked to tumor initiation and progression. Next, we observed that the expression levels of a novel lncRNA, GM50337, along with stearoyl-Coenzyme A desaturase 1 (Scd1) are significantly upregulated in PTHrP WT but not in KO tumors. We further validated a potential human orthologue lncRNA, OLMALINC, together with SCD1 that can be regulated via PTHrP in human BC cell lines. In conclusion, these novel findings could be used to develop targeted strategies for the treatment of BC and its metastatic complications.
Keyphrases
- cell cycle
- fatty acid
- endothelial cells
- poor prognosis
- cell proliferation
- squamous cell carcinoma
- long non coding rna
- signaling pathway
- single cell
- induced pluripotent stem cells
- long noncoding rna
- high fat diet induced
- type diabetes
- pluripotent stem cells
- risk factors
- epithelial mesenchymal transition
- oxidative stress
- adipose tissue
- metabolic syndrome
- risk assessment
- atrial fibrillation
- combination therapy